Specificities of broadly neutralizing anti-HIV-1 sera
- PMID: 20048699
- DOI: 10.1097/COH.0b013e32832e06fe
Specificities of broadly neutralizing anti-HIV-1 sera
Abstract
Purpose of review: Effective vaccine-elicited immunity against HIV-1 infection will likely require broadly neutralizing antibodies to interrupt the fusion-promoting functions of the viral envelope glycoprotein spikes. Efforts in this area have, however, been fraught with challenges. The handful of existing broadly neutralizing monoclonal antibodies has provided information on some of the virus' sites of vulnerability, fueling a decade of structure-informed vaccine design. The fact that very few bnmAbs have been recovered to date illustrates the poor immunogenicity of these epitopes. Recognizing that progress may require more basic information, there has been a notable shift in the field toward identifying new chinks in HIV-1's armor. These efforts are based on the observation that some infected patients develop exceptionally broad serum neutralizing antibodies responses, a better understanding of which would be valuable for vaccine efforts aimed at eliciting similar specificities.
Recent findings: New mapping methodologies are now providing an appreciation of the incidence of specificities similar to the existing known bnmAbs as well as some intriguing insights into novel specificities.
Summary: The new information emerging from mapping efforts should help to sharpen efforts to isolate new bnmAbs and moreover, may provide crucial information for the rational design of novel vaccine candidates.
Similar articles
-
Challenges for structure-based HIV vaccine design.Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Curr Opin HIV AIDS. 2009. PMID: 20048708 Review.
-
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.Science. 2013 May 10;340(6133):751-6. doi: 10.1126/science.1233989. Science. 2013. PMID: 23661761
-
Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).Mol Med Rep. 2012 May;5(5):1311-7. doi: 10.3892/mmr.2012.790. Epub 2012 Feb 14. Mol Med Rep. 2012. PMID: 22344547 Clinical Trial.
-
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144. J Infect Dis. 2010. PMID: 20170371
-
HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.Vaccine. 2012 Jun 19;30(29):4310-5. doi: 10.1016/j.vaccine.2011.11.014. Epub 2011 Nov 17. Vaccine. 2012. PMID: 22100891 Review.
Cited by
-
Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.Vaccines (Basel). 2022 Mar 2;10(3):384. doi: 10.3390/vaccines10030384. Vaccines (Basel). 2022. PMID: 35335016 Free PMC article. Review.
-
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17. J Virol. 2011. PMID: 21849452 Free PMC article.
-
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18. Nature. 2012. PMID: 23151583 Free PMC article.
-
Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.J Virol. 2010 Oct;84(20):10690-9. doi: 10.1128/JVI.01110-10. Epub 2010 Aug 11. J Virol. 2010. PMID: 20702629 Free PMC article.
-
Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Arch Virol. 2012 Jan;157(1):1-20. doi: 10.1007/s00705-011-1145-2. Epub 2011 Oct 20. Arch Virol. 2012. PMID: 22012269 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials